On the Caveats of a Multiplex Test for SARS-CoV-2 to Detect Seroconversion After Infection or Vaccination

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jun 20

PMID 35725758

Authors

Lorena O Fernandes-Siqueira

Fabiana A P Ferreira

Bruna G Sousa

Nathane C Mebus-Antunes

Thais C Neves-Martins

Fabio C L Almeida

Gustavo C Ferreira

Didier Salmon

Luciana S Wermelinger

Andrea T Da Poian

Affiliations

Soon will be listed here.

Abstract

The Covid-19 pandemic, caused by SARS-CoV-2, has resulted in over 6 million reported deaths worldwide being one of the biggest challenges the world faces today. Here we present optimizations of all steps of an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against the trimeric spike (S) protein, receptor binding domain (RBD), and N terminal domain of the nucleocapsid (N-NTD) protein of SARS-CoV-2. We discuss how to determine specific thresholds for antibody positivity and its limitations according to the antigen used. We applied the assay to a cohort of 126 individuals from Rio de Janeiro, Brazil, consisting of 23 PCR-positive individuals and 103 individuals without a confirmed diagnosis for SARS-CoV-2 infection. To illustrate the differences in serological responses to vaccinal immunization, we applied the test in 18 individuals from our cohort before and after receiving ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, our results show that the test can be customized at different stages depending on its application, enabling the user to analyze different cohorts, saving time, reagents, or samples. It is also a valuable tool for elucidating the immunological consequences of new viral strains and monitoring vaccination coverage and duration of response to different immunization regimens.

Citing Articles

IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2.

Fernandes-Siqueira L, Sousa B, Cleto C, Wermelinger L, Caetano B, Pacheco A J Clin Virol Plus. 2022; 2(4):100121.

PMID: 36349309 PMC: 9635250. DOI: 10.1016/j.jcvp.2022.100121.

Transmissible Gastroenteritis Virus Nucleocapsid Protein Interacts with Na/H Exchanger 3 To Reduce Na/H Exchanger Activity and Promote Piglet Diarrhea.

Niu Z, Xu S, Zhang Y, Kan Z, Zhang J, Liu X J Virol. 2022; 96(22):e0147322.

PMID: 36342433 PMC: 9682987. DOI: 10.1128/jvi.01473-22.

SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study.

Kucan Brlic P, Pavletic M, Lerga M, Krstanovic F, Matesic M, Miklic K Viruses. 2022; 14(9).

PMID: 36146773 PMC: 9503044. DOI: 10.3390/v14091966.

References

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Xiao T, Wang Y, Yuan J, Ye H, Wei L, Liao X . Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers. Front Med (Lausanne). 2021; 8:595773. PMC: 8005564. DOI: 10.3389/fmed.2021.595773. View

Garritsen A, Scholzen A, van den Nieuwenhof D, Smits A, Datema E, van Galen L . Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. Infect Dis (Lond). 2021; 53(7):498-512. PMC: 7967720. DOI: 10.1080/23744235.2021.1893378. View

Garcia-Beltran W, Lam E, Astudillo M, Yang D, Miller T, Feldman J . COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021; 184(2):476-488.e11. PMC: 7837114. DOI: 10.1016/j.cell.2020.12.015. View

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M . Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369(6499):77-81. PMC: 7202686. DOI: 10.1126/science.abc1932. View

Roltgen K, Powell A, Wirz O, Stevens B, Hogan C, Najeeb J . Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020; 5(54). PMC: 7857392. DOI: 10.1126/sciimmunol.abe0240. View

Shrock E, Fujimura E, Kula T, Timms R, Lee I, Leng Y . Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020; 370(6520). PMC: 7857405. DOI: 10.1126/science.abd4250. View

Ha B, Jadhao S, Hussaini L, Gibson T, Stephens K, Salazar L . Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiol Spectr. 2021; 9(2):e0045821. PMC: 8557898. DOI: 10.1128/Spectrum.00458-21. View

Peterhoff D, Gluck V, Vogel M, Schuster P, Schutz A, Neubert P . A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection. 2020; 49(1):75-82. PMC: 7441844. DOI: 10.1007/s15010-020-01503-7. View

10.

Bochnia-Bueno L, de Almeida S, Raboni S, Adamoski D, Amadeu L, Carstensen S . Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination. Diagn Microbiol Infect Dis. 2021; 102(3):115597. PMC: 8603270. DOI: 10.1016/j.diagmicrobio.2021.115597. View

11.

Becker M, Strengert M, Junker D, Kaiser P, Kerrinnes T, Traenkle B . Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun. 2021; 12(1):1152. PMC: 7896075. DOI: 10.1038/s41467-021-20973-3. View

12.

Bates T, Weinstein J, Farley S, Leier H, Messer W, Tafesse F . Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep. 2021; 34(7):108737. PMC: 7835103. DOI: 10.1016/j.celrep.2021.108737. View

13.

Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W . Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol. 2020; 58(6). PMC: 7269413. DOI: 10.1128/JCM.00461-20. View

14.

Infantino M, Manfredi M, Grossi V, Lari B, Fabbri S, Benucci M . Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies. J Med Virol. 2020; 93(3):1436-1442. PMC: 7436746. DOI: 10.1002/jmv.26422. View

15.

Landsberg H, Turcinovic J, Sullivan M, Connor J, Hamer D, Platt J . Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster. Int J Infect Dis. 2021; 114:62-64. PMC: 8556072. DOI: 10.1016/j.ijid.2021.10.053. View

16.

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View

17.

Burbelo P, Riedo F, Morishima C, Rawlings S, Smith D, Das S . Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020; 222(2):206-213. PMC: 7313936. DOI: 10.1093/infdis/jiaa273. View

18.

Machado B, Hodel K, Barbosa-Junior V, Soares M, Badaro R . The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature. Viruses. 2021; 13(1). PMC: 7823618. DOI: 10.3390/v13010040. View

19.

Saraswati K, Phanichkrivalkosil M, Day N, Blacksell S . The validity of diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG ELISAs: A review of the evidence. PLoS Negl Trop Dis. 2019; 13(2):e0007158. PMC: 6382213. DOI: 10.1371/journal.pntd.0007158. View

20.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View